Financials Biotricity, Inc.

Equities

BTCY

US09074H2031

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-05-13 pm EDT 5-day change 1st Jan Change
1.09 USD -11.02% Intraday chart for Biotricity, Inc. -9.17% -5.22%

Valuation

Fiscal Period: March 2019 2021 2022 2023 2024 2025
Capitalization 1 54.42 128.1 133 27.83 10.32 -
Enterprise Value (EV) 1 54.42 128.1 133 27.83 10.32 10.32
P/E ratio -3.54 x -5.47 x -3.41 x - - -
Yield - - - - - -
Capitalization / Revenue - - 17.4 x 2.89 x 0.86 x 0.72 x
EV / Revenue - - 17.4 x 2.89 x 0.86 x 0.72 x
EV / EBITDA - - -7,777,400 x - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 9,967 8,911 9,768 9,975 9,469 -
Reference price 2 5.460 14.37 13.62 2.790 1.090 1.090
Announcement Date 7/16/19 6/22/21 7/14/22 6/29/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2021 2022 2023 2024 2025
Net sales 1 - - 7.65 9.639 12 14.3
EBITDA - - -17.11 - - -
EBIT 1 - - -18.02 -15.41 -7.2 -4.9
Operating Margin - - -235.55% -159.87% -60% -34.27%
Earnings before Tax (EBT) - - -29.13 - - -
Net income -8.592 -15.49 -30.22 - - -
Net margin - - -395.01% - - -
EPS -1.542 -2.628 -3.990 - - -
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/16/19 6/22/21 7/14/22 6/29/23 - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 1.807 1.93 2.149 2.056 2.381 2.459 2.742 3.021 2.891 2.973 3.2
EBITDA -4.999 -4.635 -4.626 -4.385 -4.287 -4.112 - - - - -
EBIT 1 -5.169 -4.735 -5.114 -4.477 -4.433 -4.252 -3.454 -2.316 -2.186 -1.282 -1.4
Operating Margin -286% -245.34% -237.99% -217.75% -186.13% -172.9% -125.93% -76.69% -75.59% -43.11% -43.75%
Earnings before Tax (EBT) -10.75 -7.11 -5.612 -4.776 -4.693 -4.517 - - - - -
Net income -11 -7.343 -5.982 -5.024 -4.904 -4.747 - - - - -
Net margin -608.5% -380.44% -278.38% -244.37% -205.95% -193.05% - - - - -
EPS -1.536 -0.8940 -0.6660 -0.5880 -0.5640 -0.5460 - - - - -
Dividend per Share - - - - - - - - - - -
Announcement Date 11/4/21 2/14/22 7/14/22 8/15/22 11/14/22 2/14/23 6/29/23 8/14/23 11/14/23 2/20/24 -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 7/16/19 6/22/21 7/14/22 6/29/23 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.09
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. BTCY Stock
  4. Financials Biotricity, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW